The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database

Background Pancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine neoplasms (NENs) for which little is known about their clinical features, treatment options, and survival prognosis. The purpose of this study is to evaluate the risk factors affecting the overall survival (OS) and cancer-specific survival (CSS) in patients with grade 1 pNETs (G1 pNETs) and to provide a new theoretical basis for clinical diagnosis and treatment. Methods A retrospective analysis of individuals with G1 pNETs registered in the Surveillance, Epidemiology, End Results (SEER) database was performed. Risk factors affecting OS and CSS were analyzed using Kaplan-Meier analysis, Cox proportional hazards model, and Fine-Gray competing-risk model. Results A total of 751 patients were included, most of whom were white (77.2%) women (53.9%) under the age of 60 years (54.9%), of whom 66 died of pNETs (8.78%) and 34 died of other causes (4.52%). Patients who were older than 60 years at diagnosis (hazard ratio [HR] = 1.866, 95% confidence interval [CI]: 1.242-2.805) had worse OS. And stage in the regional extent (HR = 1.777, 95% CI: 1.006-3.137) or distance extent (HR = 4.540, 95% CI: 2.439-8.453) had worse OS. Patients who delayed treatment after diagnosis had shorter CSS (delayed treatment < 1 month: HR = 1.933, 95% CI: 0.863-4.333; delayed treatment ≥ 1 month: HR = 2.208; 95% CI:1.047-4.654). Patients with lymph node metastasis (HR = 1.989, 95% CI: 1.137-3.479) or distant metastasis (HR = 5.625, 95% CI: 1.892-16.726) had worse CSS. Acceptance of surgery can significantly improve the patient’s OS and CSS. OS (partial pancreatectomy [PP]: HR = 0.350, 95% CI: 0.182-0.672; pancreatectomy and duodenectomy [PD]: HR = 0.426, 95% CI: 0.222-0.815; total pancreatectomy [TP]: HR = 0.495, 95% CI: 0.193-1.267). CSS(PP: HR = 0.148, 95% CI: 0.0054-0.401; PD: HR = 0.332, 95% CI: 0.150-0.730; TP: HR = 0.69, 95% CI: 0.254-1.872). Conclusion Age and stage were identified as independent risk factors for OS. Delayed treatment, N stage and M stage were independent risk factors for CSS. Only surgery was identified as independent protective factors for OS and CSS.

[1]  Dongsheng Zhang,et al.  Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study , 2022, Frontiers in endocrinology.

[2]  R. Rossi,et al.  The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues , 2022, Journal of clinical medicine.

[3]  N. Xu,et al.  Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). , 2022, European journal of cancer.

[4]  D. Murphy,et al.  Real‐world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours , 2022, Journal of neuroendocrinology.

[5]  M. V. van Velthuysen,et al.  Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Severi,et al.  Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors , 2022, JAMA network open.

[7]  Xiao Wang,et al.  Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[8]  Jianguo Sun,et al.  Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States , 2021, JAMA network open.

[9]  T. Giordano,et al.  Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  H. Friess,et al.  Morphology Matters , 2021, The American journal of surgical pathology.

[11]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Metz,et al.  NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy , 2020, The Journal of Nuclear Medicine.

[13]  Jeffrey E. Lee,et al.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.

[14]  R. Higuchi,et al.  Evaluation of the Site and Frequency of Lymph Node Metastasis with Non-Functioning Pancreatic Neuroendocrine Tumor , 2019, European Surgical Research.

[15]  Peter Schirmacher,et al.  The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.

[16]  K. Matsuo,et al.  Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately , 2019, Annals of surgical oncology.

[17]  P. Rancoita,et al.  The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  M. Dietel,et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.

[19]  J. Qian,et al.  Development and Validation of a Nomogram for Predicting Overall Survival in Pancreatic NeuroendocrineTumors12 , 2018, Translational oncology.

[20]  Seung‐Mo Hong,et al.  Recent updates on grading and classification of neuroendocrine tumors. , 2017, Annals of diagnostic pathology.

[21]  J. Tseng,et al.  National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors. , 2017, Journal of the American College of Surgeons.

[22]  M. Falconi,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours , 2017, Neuroendocrinology.

[23]  A. Scarpa,et al.  Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. , 2016, Surgery.

[24]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[25]  S. Tretli,et al.  Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010 , 2015, Neuroendocrinology.

[26]  P. Ruszniewski,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[27]  S. Roman,et al.  Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States , 2014, Annals of Surgical Oncology.

[28]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Jae Hyuk Lee,et al.  Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study , 2012, Cancer research and treatment : official journal of Korean Cancer Association.

[30]  J. Hainsworth,et al.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study , 2011, The Lancet.

[31]  A. Scarpa,et al.  Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. , 2011, Surgery.

[32]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[33]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[34]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[35]  Domenico Coppola,et al.  The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.

[36]  D. Coppola,et al.  The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. , 2010, Pancreas.

[37]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Jian-ping Wang,et al.  Clinicopathologic analysis of eight cases of pancreatic carcinoid tumors. , 2009, Chinese Medical Journal.

[39]  T. McDade,et al.  Pancreatic neuroendocrine tumors , 2009, Cancer.

[40]  M. Papotti,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification , 2008, Neuroendocrinology.

[41]  L. Kvols,et al.  Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? , 2008, Cancer control : journal of the Moffitt Cancer Center.

[42]  J. Soga.  Carcinoids of the pancreas , 2005, Cancer.

[43]  J. Howard,et al.  Carcinoid tumors of the pancreas , 1998, International journal of pancreatology : official journal of the International Association of Pancreatology.